Phathom Pharmaceuticals Q1 2024 Earnings Report $4.88 -0.13 (-2.59%) As of 04/4/2025 04:00 PM Eastern Earnings HistoryForecast Phathom Pharmaceuticals EPS ResultsActual EPS-$1.42Consensus EPS -$1.43Beat/MissBeat by +$0.01One Year Ago EPSN/APhathom Pharmaceuticals Revenue ResultsActual Revenue$1.91 millionExpected Revenue$2.76 millionBeat/MissMissed by -$850.00 thousandYoY Revenue GrowthN/APhathom Pharmaceuticals Announcement DetailsQuarterQ1 2024Date5/9/2024TimeN/AConference Call ResourcesConference CallPress ReleasePHAT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads Phathom Pharmaceuticals Earnings Headlines‘Saturday Night Live’ cast member breaks silence on health issueApril 5 at 3:01 PM | msn.comPhathom Pharmaceuticals' (PHAT) "Buy" Rating Reiterated at GuggenheimApril 5 at 3:17 AM | americanbankingnews.comWill the U.S. military protect this $10B gold mine?You don’t need the gold price to move another inch for this company to potentially re-rate several hundred percent higher. All it takes is the market realizing the U.S. military has the DRC’s back - and that moment may be days away. The last time political risk collapsed on a project like this, early investors saw once-in-a-decade gains.April 6, 2025 | Golden Portfolio (Ad)Phathom Pharmaceuticals (NASDAQ:PHAT) Receives "Buy" Rating from Needham & Company LLCApril 5 at 1:59 AM | americanbankingnews.comContrasting Quoin Pharmaceuticals (NASDAQ:QNRX) and Phathom Pharmaceuticals (NASDAQ:PHAT)April 4 at 3:27 AM | americanbankingnews.comPhathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade)April 3 at 3:37 PM | seekingalpha.comSee More Phathom Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phathom Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your email. Email Address About Phathom PharmaceuticalsPhathom Pharmaceuticals (NASDAQ:PHAT), biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.View Phathom Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
